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ABSTRACT Analysis of antigen dissociation provides insight into peptide presentation modes of folded human leukocyte
antigen (HLA) molecules, which consist of a heavy chain, b2-microglobulin (b2m), and an antigenic peptide. Here we have
monitored peptide-HLA interactions and peptide dissociation kinetics of two HLA-B27 subtypes by ﬂuorescence depolarization
techniques. A single natural amino-acid substitution distinguishes the HLA-B*2705 subtype that is associated with the
autoimmune disease ankylosing spondylitis from the non-disease-associated HLA-B*2709 subtype. Peptides with C-terminal
Arg or Lys represent 27% of the natural B*2705 ligands. Our results show that dissociation of a model peptide with a C-terminal
Lys (GRFAAAIAK) follows a two-step mechanism. Final peptide release occurs in the second step for both HLA-B27 subtypes.
However, thermodynamics and kinetics of peptide-HLA interactions reveal different molecular mechanisms underlying the ﬁrst
step, as indicated by different activation energies of 95 6 8 kJ/mol (HLA-B*2705) and 150 6 10 kJ/mol (HLA-B*2709). In HLA-
B*2709, partial peptide dissociation probably precedes fast ﬁnal peptide release, while in HLA-B*2705 an allosteric mechanism
based on long-range interactions between b2m and the peptide binding groove controls the ﬁrst step. The resulting peptide
presentation mode lasts for days at physiological temperature, and determines the peptide-HLA-B*2705 conformation, which is
recognized by cellular ligands such as T-cell receptors.
INTRODUCTION
Major histocompatibility complex (MHC) class I molecules
play a central role in the initiation and propagation of im-
mune responses and the recognition of intracellular patho-
gens through the presentation of antigenic peptides to cytotoxic
CD81-T cells (1). The heterotrimeric MHC molecule (pMHC)
consists of a highly polymorphic transmembrane heavy chain
(HC), a light chain, b2-microglobulin (b2m), and a peptide
(Fig. 1). Peptidic fragments of self- or non-self-proteins are
loaded on HC/b2m heterodimers in the endoplasmic retic-
ulum followed by transport of the heterotrimer to the cell sur-
face (2). The peptides, usually 8–10 amino acids in length,
present anchoring backbone atoms at or near both termini as
well as MHC-binding side chains at position 2 and at the
C-terminus (3). Once at the cell surface, pMHC serve as po-
tential targets for cytotoxic T lymphocytes.
One of the most striking features of human MHC (HLA)
class I genes is their potential association to diseases (4). For
example, individuals with HLA-B27 exhibit an ;90-fold-
higher risk to acquire the autoimmune disease ankylosing
spondylitis (AS) than HLA-B27-negative individuals (5–8).
Furthermore, even HLA-B27 subtypes may be differentially
associated to AS: HLA-B*2705 is AS-associated, while
HLA-B*2709 is not (9). The only difference between the
HLA-B*2705 and HLA-B*2709 molecules (B*2705 and
B*2709 in short) is a natural substitution of a single amino
acid at the floor of the peptide-binding groove, Asp116 in
B*2705 to His116 in B*2709 (10). The presence of Asp or
His at HC residue 116 results in;80–90% of shared and 10–
20% of differentially bound peptide ligands that can be eluted
from the two HLA-B27 molecules (11). All B*2705 ligands
not bound to B*2709 had a C-terminal basic (Arg, Lys) or Tyr
residue, while a small percentage of peptides containing
C-terminal Arg or Tyr are shared, i.e., bind to both subtypes (11).
The differential association of HLA-B27 subtypes to AS
as well as the differential binding of subsets of natural ligands
is expected to provide unique insight into the pathogenic role
of HLA-B27, as the mechanism of disease association is still
elusive. Consequently, elucidation of the molecular mech-
anisms underlying the strong association of HLA-B27 with
AS requires an understanding of the structural and dynamic
properties of the pMHC and interacting proteins, although
other factors may also determine AS pathogenesis. The high
resolution x-ray structures of B*2705 and B*2709 with the
model peptide m9 (GRFAAAIAK) (which binds to both
subtypes in vitro (12)) as well as thermodynamic analyses
(13,14), fluorescence depolarization, and molecular dynam-
ics simulation studies (13) provide a clue for the lack of
peptides with pLys9 in B*2709. The e-amino group of pLys9
forms a salt bridge with Asp116 in B*2705, whereas only a
hydrogen bond exists between His116 and pLys9 in B*2709
(12). Despite the peptide’s basic C-terminal Lys, the two
complexes with the m9 peptide display virtually identical
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crystal structures (12), however, the real-time dynamic prop-
erties are clearly different (13). Among various studies of
thermodynamic and kinetic properties of class I pMHCs (15–
19), a few have addressed HLA-B27 molecules (13,14,20–23).
These investigations included analyses of the thermal unfolding
of B*2705, complexed with various peptides, using circular
dichroism spectroscopy (14,20,22,23), differential scanning
calorimetry (14,23), and fluorescence depolarization (13,21–
23). The results of these studies show the importance of
peptide residues at p1, p3, and p9 as well as of residue Cys67.
In this article, we present a systematic comparison of the
thermodynamic behavior of the m9 peptide bound to B*2705
and B*2709. We compared thermodynamic parameters of
peptide dissociation with those of complex unfolding by using
the fluorescence anisotropy of a fluorescent label bound to
the peptide and the temperature-dependent fluorescence emis-
sion of endogenous tryptophans (Fig. 1), respectively, as ob-
servables to identify the primary event in complex dissociation.
Extensive investigations of peptide dissociation kinetics and
their evaluation by kinetic models reveal two different mech-
anistic principles of m9 dissociation from B*2709 and
B*2705. A specific effect of b2m on peptide presentation was
observed for B*2705, suggesting long-range intermolecular
peptide stabilization effects.
MATERIALS AND METHODS
Protein preparation
Complexes of the subtypes B*2705 and B*2709 with the peptide m9
(GRFAAAIAK) were prepared as described previously (12,13,24,25). The
synthetic m9-peptide as well as its fluorescent derivatives labeled with Lucifer
Yellow (LY, Molecular Probes, Eugene, OR) in position C6 (GRFAAC
(-LY)IAK; m9-C6-LY) and C8 (GRFAAAIC(-LY)K; m9-C6-LY), respec-
tively, were purchased from Biosynthan (Berlin, Germany). Briefly, hetero-
trimeric HLA-B27-m9 complexes (HC/b2m/peptide) complexes were refolded
from 6 M urea in the presence of the respective peptide. This procedure also
applies for the refolding of b2m alone. Refolding of pMHC with b2m-
dimers, covalently linked via a disulfide bridge between two b2m mono-
mers, was performed as described for pMHC formation with monomeric
b2m, except that oxidized and reduced gluthation were employed in equi-
molar amounts (5 mM). After size-exclusion chromatography, the concen-
trations of pMHC in 10 mM phosphate buffer, pH 7.5, 150 mM NaCl were
adjusted to A426 ¼ 0.0012 OD using the absorption band of Lucifer Yellow
(lmax ¼ 426 6 2 nm).
Thermal complex unfolding
Thermal unfolding of pMHC and isolated b2m was measured in the tem-
perature range from 5C to 85C, with an average heating rate of 0.6C per
min, by observing the spectral change of the fluorescence emission of tryp-
tophan at equilibrium conditions. Intrinsic tryptophans were excited at lex¼
280 nm. Tryptophan fluorescence spectra were recorded between 300 and
450 nm using a standard fluorescence spectrometer (Spex-FluoroMax, HORIBA
Jobin Yvon, Edison, NJ). The temperature-dependent unfolding was ana-
lyzed by calculating the quotient of the intensities at 360 and 320 nm
(13,26). This eliminates the temperature-dependent baseline shift due to the
decrease in emission intensity of tryptophan with increasing temperature.
Thermodynamic parameters, such as the enthalpy and entropy changes of
the unfolding process as well as melting temperatures Tm, were obtained by
fitting the following equations to the emission intensity quotients I360/I320 of
tryptophan using the least-square method. Either Eq. 1, representing a two-
state transition for a single process, or Eq. 2, describing a three-state tran-
sition when two stepwise processes were observed, was used to fit the data (26):
IðTÞ ¼
r0b1 sbT1 ðr0d1 sdTÞexp DH
0
p 1TDS
0
p
RT
 
11 exp
DH0p1TDS0p
RT
  ; (1)
FIGURE 1 Model of the crystal structure of the HLA-
B*2705 ectodomain loaded with the m9 peptide (1JGE).
The peptide is displayed in red and yellow. The yellow
color marks the two main anchor residues of the peptide,
pArg2 and pLys9, as well as the amino-acid positions p6
and p8, which were exchanged to cysteine and modified
with the fluorescent label LY in our studies. The tryptophan
residues in b2m (dark gray) and in HC (light gray) are
colored in green and turquoise, respectively. Amino acid
116 at the floor of the peptide binding groove is colored in
black. (Right) Closeup of the peptide binding groove.
IðTÞ ¼
r0b1 sbT1 ðr0d11 sd1TÞexp DH
0
p11TDS
0
p1
RT
 
1 ðr0d21 sd2TÞexp DH
0
p21TDS
0
p2
RT
 
11 exp
DH0p1 1TDS0p1
RT
 
1 exp
DH0p21TDS0p2
RT
  ; (2)
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with
Tm1;2 ¼
DH
0
p1;2
DS
0
p1;2
: (3)
These equations involve six (two-state) and 10 (three-state) fitting param-
eters, respectively; the intensity quotient of the folded state (native protein),
r0b, and of the unfolded or dissociated state, r0d1,2; the temperature-
dependence of the intensity quotient of the folded state, sb, and of the un-
folded or dissociated state, sd1,2; and the enthalpy change DH
0
p1;2; and the
entropy change, DS0p1;2; for the two- or three-state unfolding/dissociation
reaction, the thermodynamic parameters being determined at the midpoint
of each transition.
Thermodynamics of peptide dissociation
Temperature-induced peptide dissociation from the pMHC was measured as
described (13) by detection of the change in the stationary anisotropy of LY
covalently bound to m9 in the temperature range from 5C to 85C. An
average heating rate of 0.6C per min was applied. Lucifer Yellow was ex-
cited at lex¼ 428 nm and the steady-state anisotropy was determined within
a time-correlated single photon-counting setup (27) by collecting the integral
emission intensity for l $ 495 nm, parallel Ik, and perpendicular I?, with
respect to the linearly polarized excitation light. Data evaluation was per-
formed as described above applying Eq. 1, assuming a two-state transition.
The anisotropy r(T) instead of the fluorescence intensity I(T) was used as the
temperature-dependent parameter in Eq. 1. The anisotropy values were cal-
culated according to Eq. 4:
rðtÞ ¼ IkðtÞ  I?ðtÞ
IkðtÞ1 2I?ðtÞ: (4)
Kinetics of peptide dissociation
The temporal dissociation behavior of the LY-labeled peptides, m9-C6-LY
and m9-C8-LY, from the HLA-B*2709 and B*2705 complexes, was moni-
tored by measuring the time-dependent change in the stationary fluorescence
anisotropy. Lucifer Yellow was excited at lex ¼ 428 nm, and the anisotropy
as a function of time was recorded at 530 nm using a standard fluorescence
spectrometer (Spex-FluoroMax, Jobin Yvon). The G-factor was G ¼ 0.67.
The anisotropy values were calculated according to Eq. 4 and automatically
corrected for the G-factor during the measurement. Peptide-dissociation
kinetics was recorded at five different temperatures below the transition
temperature of temperature-induced peptide dissociation. The sample was
equilibrated at the given temperature. To avoid rebinding of the labeled
peptide, peptide dissociation from the complex was investigated with a 100-
fold molar excess of unlabeled peptide m9. The measurement was started
after addition of unlabeled m9.
Emission intensities at 530 nm (lexc ¼ 426 nm) were averaged for 5 s, in
a time interval of 14 or 25 s, which sets the time resolution of the experiment.
The final point of the measurement was reached when the anisotropy of the
sample was equal to the value of the free labeled peptide, m9-C6-LY or
m9-C8-LY, at the given temperature.
Peptide-dissociation time traces were fitted with a mono- or biexponential
decay law (Eq. 5) depending on the subtype, label position, and temperature:
rðtÞ ¼ +
n
i¼1
Aiexpðt=tiÞ: (5)
A stretched exponential function was applied for peptide dissociation
kinetics from B*2705 complexes at higher temperatures, with h being a
heterogeneity parameter (28):
rðtÞ ¼ +
n
i¼1
Aiexp½ðt=tiÞ
1
hi : (6)
RESULTS AND DISCUSSION
Spectroscopic characterization of the
HLA-molecules complexed with the
ﬂuorescently labeled m9 peptide
The absorption spectrum of the HLA*B2705 and HLA*B2709
molecules complexed with the m9-C6-LY peptide is char-
acterized by a weak absorption band centered at 428 nm,
which is due to the absorption of the fluorescent label LY
attached to the peptide, and a strong band at 280 nm, rep-
resenting the transition of LY to higher electronic states and
the absorption of tryptophan residues in the heavy chain and
b2m (Fig. 2 A). The emission spectra in Fig. 2 B show the
fluorescence of LY with a maximum at lmax ¼ 532 6 1 nm
as well as the fluorescence of tryptophan with an emission
maximum at lmax ¼ 340 6 1 nm. For comparison, the ab-
sorption and emission spectra of b2m alone, which contains
two tryptophan residues (see Fig. 1), are displayed in Fig. 2,
C and D.
Comparison of thermodynamic parameters
describing pMHC denaturation
and peptide dissociation
pMHC stability was assessed for both subtypes by investi-
gating their thermal behavior when loaded with the m9 pep-
tide. Temperature-induced peptide dissociation and global
unfolding experiments were performed to extract thermody-
namic parameters, such as the apparent enthalpy and entropy,
to identify the primary event in complex unfolding. Moni-
toring the fluorescence polarization or anisotropy of the
labeled peptide is especially suited to directly follow the
mole fraction of the peptide molecules bound to the complex
and the fraction of peptides free in solution (13,15,21,22).
The left column in Fig. 3 shows 1), peptide dissociation
from B*2709 as observed by steady-state fluorescence an-
isotropy changes of the fluorescent dye LY bound to m9 at
position 6 (Fig. 3 A); 2), pMHC unfolding as observed by the
temperature-induced changes of the tryptophan emission
(Fig. 3 B); and 3), unfolding of b2m via tryptophan emission
(Fig. 3 C). A single two-state transition for peptide disso-
ciation was observed for m9 dissociation from the B*2709-
m9-C6-LY-complex with a transition temperature of Tm ¼
466 2C (13) (Fig. 3 A). The temperature-dependent changes
in tryptophan emission, shown as the quotient of the in-
tensities at the red and blue edges of the spectrum, 360 nm
and 320 nm, reveal two transitions for complex unfolding
(Fig. 3 B), whereas for b2m alone, only one transition was
observed (Fig. 3 C). For a better comparison of these mul-
tiple transitions, the changes in tryptophan fluorescence and
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in LY anisotropy as a function of temperature are presented
as their first derivatives in the middle column (Fig. 3, D–F).
The bell-shaped curves represent the respective transition
with the transition temperature at the maximum of the curve.
The dissociation of m9-C6-LY from B*2709 (Tm ¼ 46 6
2C) coincides with the first transition observed in global
unfolding (Tm ¼ 46 6 3C, Fig. 3, A, B, D, and E) (13),
whereas the second transition (Tm¼ 656 3C (Fig. 3, B and
E) coincides with b2m unfolding at Tm ¼ 64 6 3C (Fig.
3 C). Thus, in B*2709, the release of m9 and unfolding of the
heavy chain are tightly coupled, while b2m melts at higher
temperatures at the intrinsic b2m melting temperature. In
contrast to B*2709, unfolding of the B*2705-m9-C6-LY
complex is characterized by a single transition at ;65C
(Fig. 3 H). This transition temperature coincides with the
peptide dissociation temperature (Fig. 3 G) and is also close
to the temperature of b2m unfolding. For B*2705 peptide
release, unfolding of heavy chain and b2m therefore seems
to occur in a cooperative way (Fig. 3, G–I). Despite the
differences in thermal unfolding between B*2705-m9 and
B*2709-m9, our results suggest that m9 dissociation is cor-
related with the initial events in thermal pMHC unfolding
and is tightly coupled to HC unfolding. Similar conclusions
as for m9 dissociation were drawn from peptide dissociation
and complex unfolding experiments of the self-peptide TIS
(RRLPIFSRL) complexed with the subtypes B*2705 and
B*2709 (23). In the case of the TIS-peptide (TIS-C6-LY),
the transition temperatures for peptide dissociation from
both subtypes (Tm ¼ 58C and Tm ¼ 60C for B*2705 and
B*2709, respectively), are lower than the transition temper-
ature of b2m unfolding (Tm ¼ 64C), similar to B*2709-m9.
A closer look at the unfolding of B*2705-m9, however,
reveals that peptide dissociation in B*2705-m9 could as well
be initiated by the dissociation and subsequent unfolding of
b2m as the transition temperature of peptide dissociation
of 65C coincides with the melting temperature of b2m. To
test this model of b2m-induced peptide dissociation, we
reconstituted the subtype HLA-B*2705 with a destabilized
b2m molecule. In the experiment described here, destabili-
zation was achieved by a dimeric b2m form. The b2m-dimer,
consisting of two b2m-molecules covalently attached to each
other via a disulfide bond, exhibits a reduced thermal stabil-
ity as compared to the native b2m with a transition tem-
perature of Tm ¼ 58 6 1C (Fig. 4 A). If b2m properties
determine complex unfolding and peptide dissociation for
strong peptide binders, we will expect m9 dissociation from
the B*2705 complex to coincide with b2m dimer melting,
which occurs at a transition temperature 7C lower than that
of the monomer. Our results show that the transition tem-
perature for m9 dissociation from B*2705 complexed with
the b2m-dimer, Tm ¼ 59 6 2C, is indeed ;7C lower than
that of B*2705 complexed with the b2m-monomer, Tm ¼
66 6 1C (Fig. 4 B). Thus, the interaction of the thermally
less stable b2m dimer with the HC in the HLA-B*2705-m9-
C6-LY complex results in a reduction of thermal complex
stability and a decrease of the transition temperature for
peptide dissociation. This correlation clearly supports our
hypothesis that m9 release from B*2705 depends on the
properties of b2m, even though it may turn out that this
correlation is not based on the reduced thermal stability of
the b2m dimer, but is caused by an impaired temperature-
dependent interaction of the dimer with the HC.
In a more general way, our results on the subtypes B*2705
and B*2709 show that both the peptide interaction with a
given subtype and the properties of b2m are required for
stabilization of the HC fold. For a weak peptide binder (here
m9 in B*2709), peptide release causes HC unfolding and
complex dissociation; but for a strong peptide binder (here
FIGURE 2 Sample characterization. Absorption- (A)
and emission spectra (B) of the B*2705-m9-C6-LY.
Absorption- (C) and emission spectra (D) of b2m. Lucifer
Yellow and intrinsic tryptophans were excited at lexc ¼
428 nm and lexc ¼ 280 nm, respectively. Conditions: 0.3
mM HLA-complex or 0.3 mM b2m dissolved in 10 mM
phosphate buffer, 150 mM NaCl, pH 7.5.
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m9 in B*2705), the impaired interaction of b2m with the HC
leads to b2m dissociation, causing peptide dissociation and
complex unfolding.
In our case, the strong binding properties of m9 to the
B*2705 complex molecule are a consequence of the salt
bridge between Asp116 in the F-pocket at the bottom of
the peptide binding groove and the C-terminal basic Lys of
the peptide (12). Systematic variation of the p9 residue in the
GRAFVTIGK peptide, which shares amino-acid positions 1,
2, 7, and 9 with m9, showed that the basic amino acids Lys
and Arg are by far the strongest anchors (20). Peptides with
such basic C-terminal anchors account for ;27% of the
natural B*2705 ligands (11,29), a number that underscores
the relevance of our results.
Kinetics of peptide dissociation
Kinetic peptide dissociation experiments were performed to
further explore the differences between HLA-B*2705 and
HLA-B*2709 molecules complexed with the m9 peptide to
gain an understanding of the effect of the natural Asp116His
exchange on peptide stability. Temperature-dependent kinetics
of peptide dissociation allows for the evaluation of activation
energies of peptide dissociation. We used two LY-reporter
positions for peptide dissociation: p6, close to middle of the
peptide and p8, close to the C-terminus. Peptide dissociation
kinetics from the trimeric HLA-B27 complexes were in-
vestigated by monitoring the stationary anisotropy of LY
bound to m9 as a function of time and temperature (Fig. 5).
The stationary anisotropy at time zero, the starting point of
the dissociation kinetics at a given temperature, displays
anisotropy values between 0.06 and 0.2 in the temperature
range between 22C and 61C, respectively. These values
reflect the steric restriction of the label as well as the peptide
flexibility inside the peptide binding groove at a given tem-
perature (13). A decreasing initial anisotropy with increasing
temperature in the temperature range below the transition
temperature of peptide dissociation is due to faster label and
peptide dynamics as well as the reduction in steric restriction
caused by constituents of the peptide binding groove. At
infinite times, the endpoint of the peptide dissociation time
trace, the anisotropy value equals the value of the respective
FIGURE 3 Comparison of peptide dissociation and complex unfolding. (A) Temperature-dependent anisotropy of the LY-labeled complex HLA-B*2709-
m9-C6-LY; (B) intensity quotients I360nm/I320nm of the tryptophan fluorescence of the complexes; and (C) b2m unfolding. Data were fitted according to the two-
state or three-state model. (D,G) Derivatives of the anisotropies of the LY-labeled complexes HLA-B*2709/05-m9-C6-LY and E/H derivatives of the intensity
quotients I360nm/I320nm of the tryptophan fluorescence of the complexes. (F,I) Derivatives of the intensity quotients I360nm/I320nm of the tryptophan fluorescence
of b2m (in both figures, the same set of data is displayed). All derivatives are fitted applying a Gaussian function. Conditions were chosen as in Fig. 2.
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peptide free in solution. These anisotropy values were mea-
sured in independent experiments (data not shown) and in-
corporated into the anisotropy time traces as the end-value
rN (Table 1).
The time traces shown in Fig. 5 reveal distinct differences
both in the kinetics of peptide dissociation depending on
subtype as well as reporter group position. In agreement with
the thermodynamic data for peptide dissociation described in
the previous section, the kinetics at a given temperature are
faster by a factor of;100 for peptide dissociation from B*2709,
the less stable subtype in complex with m9, than from the
B*2705 complex (Fig. 5). At physiological temperature, the
main time constants for m9-C6-LY dissociation from B*2705
and B*2709 are t ¼ 306 h (1.13 106 s) and t ¼ 3.9 h (1.43
104 s), respectively (see Table S1, Supplementary Material).
Interestingly, the incorporation of LY in position p8 results
in a stabilization of the complex as shown by the slower
peptide-dissociation kinetics (Fig. 5). The higher initial an-
isotropy values for m9-C8-LY in both subtypes, however,
are due to a higher steric restriction caused by constituents of
the peptide-binding groove (12).
The time traces of peptide dissociation were fitted with
a mono- or biexponential decay law depending on label
position and temperature. In the case of m9-C6-LY, all time-
traces for B*2705 and B*2709 were fitted with two ex-
ponential functions according to Eq. 5. With increasing
temperature, the relative amplitude of the fast time constant
increases, thereby lowering the relative amplitude of the
slower time. At higher temperatures (.50C), the discrete
exponential was substituted with a stretched exponential func-
tion (Eq. 6), to yield better fit results for peptide dissociation
from B*2705. The occurrence of stretched exponentials in
the description of biological processes can be interpreted as a
heterogeneity within the biological system that may result in
a distribution of time constants (28). In contrast, the kinetics
of m9-C8-LY dissociation from both subtypes are mono-
exponential at low temperatures, while at higher tempera-
tures the dissociation from HLA-B*2709-m9-C8-LY could
be best fitted by applying a biexponential decay function.
Peptide dissociation kinetics from HLA-B*2705-m9-C8-LY
could be best approximated by a stretched exponential at
high temperatures (.50C), as in the case of HLA-B*2705-
m9-C6-LY.
Kinetic model of m9 dissociation
The temperature dependence of the apparent time constants
and amplitudes of the data shown in Fig. 5 was analyzed
using a kinetic model that was developed on the basis of our
experimental observations and current ideas about peptide
dissociation from MHC class I complexes (13,15,16,20).
Biphasic peptide dissociation processes were already ob-
served for MHC class I complexes (15,16), but have been
controversially discussed. In HLA-A2 complexes, the obser-
vation of biexponential kinetics was interpreted as the result
of two pathways for peptide dissociation, from the fully
assembled heterotrimer and from a b2m-depleted HC/peptide
heterodimer (15). On the other hand, biphasic peptide dis-
sociation kinetics in HLA-A2 molecules has been interpreted
to result from two conformations in the fully assembled
heterotrimer (16). In extension of these previous studies, we
simulated our experimental data with a kinetic model, which
allows an analysis of the activation energies for peptide
dissociation based on the microscopic rate constants. Since
we observed at most two time constants in our data sets for
peptide dissociation from the B*2705 and B*2709 com-
plexes, the following kinetic model is sufficient to describe
our data properly:
Pbound ! k1
k1
Pintermediate !k2 Punbound: (7)
Here, m9 dissociation is interpreted as a two-step process,
with the first step representing an equilibrium between the
FIGURE 4 Thermal stability of b2m monomer and b2m dimer. (A)
Unfolding of b2m as a monomer and a covalently linked dimer in solution;
melting temperatures are Tm (monomer)¼ 65C and Tm (dimer)¼ 55C. (B)
Peptide dissociation from HLA-B*2705 with b2m as a monomer and dimer;
temperatures for peptide dissociation are Tm (monomer) ¼ 67C and Tm
(dimer) ¼ 59C. Conditions were chosen as in Fig. 2.
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peptide-bound state (Pbound) and an intermediate state
(Pintermediate), described by the rate constants k1 and k1.
The full release of the peptide (Punbound) is described by the
slower irreversible process with a rate constant k2. In the
experiment, rebinding of the fluorescently-labeled peptide
was prevented using an excess of unlabeled peptide. The events
after peptide dissociation, such as concomitant complex un-
folding in the case of B*2705 or unfolding of the heavy
chain and dissociation of b2m in the case of B*2709, are not
included in the model, because they are not accessible via
peptide dissociation kinetics.
Using Eqs. 8–17 (see Appendix), the kinetic model was
applied to the data displayed in Fig. 5. The time traces were
fitted at all temperatures with one set of five parameters for
the dissociation of m9-C6-LY (Eq. 15: k1, k1, k2, [Pbound]0
as the initial concentration of peptides bound to the HLA-
complex (Eq. 14), and a temperature-dependent offset (rN),
which accounts for the anisotropy of the free peptide) and
with one set of three parameters for the dissociation of m9-
C8-LY (Eq. 17: k1, [Pbound]0 and rN). The time constant
t1 from the biexponential least-squares fits at each temper-
ature (Fig. 5, black traces) was taken as a first estimate for
the rate constant k1 at the respective temperature. The initial
value for k2 was taken from the slowest 1/e decay time of
each time trace from the biexponential least-squares fit (see
Table S1, Supplementary Material). The rates for k1 and k1
FIGURE 5 Time-dependent change in anisotropy
of LY-labeled HLA-B27-complexes at different
temperatures. (Top) Subtype HLA-B*2709 com-
plexed with m9-C6-LY (A) and m9-C8-LY (B) at
22, 26, 30, 34, and 37C. (Bottom) Subtype HLA-
B*2705 complexed with m9-C6-LY (C, at 26, 30,
37, 50, and 60C) and m9-C8-LY (D, at 26, 30, 37,
50, 55, and 61C). Black lines represent mono- or
biexponential fits (dependent on temperature, a
stretched exponential had to be applied in HLA-
B*2705, panel D). Colored lines represent the model
fits according to Eq.12 and 17 to the respective data
set. (A stretching factor 1/h was considered in Eq. 17
for data at 55 and 61C, displayed in D.)
TABLE 1 Parameters from the kinetic model
Subtype Temperature K k1 s
1 k1 s
1 k2 s
1 rN r0–rN h
B*2709-m9-C6-LY 295 6.67 3 105 5.00 3 105 1.22 3 105 0.030 0.120 —
299 1.18 3 104 9.09 3 105 2.78 3 105 0.028 0.111 —
303 2.87 3 104 2.27 3 104 4.76 3 105 0.026 0.103 —
307 5.56 3 104 4.55 3 104 1.22 3 104 0.024 0.099 —
310 1.18 3 103 9.09 3 104 1.54 3 104 0.022 0.094 —
B*2705-m9-C6-LY 299 1.11 3 103 9.09 3 104 1.96 3 107 0.028 0.110 —
303 1.43 3 103 2.22 3 103 1.11 3 106 0.026 0.112 —
310 3.33 3 103 4.35 3 103 1.50 3 106 0.022 0.095 —
323 1.11 3 102 1.33 3 102 2.38 3 105 0.017 0.071 —
333 5.55 3 102 6.67 3 102 2.82 3 104 0.017 0.057 —
B*2709-m9-C8-LY 295 4.54 3 106 — — 0.028 0.152 —
299 7.69 3 106 — — 0.026 0.150 —
303 1.82 3 105 — — 0.024 0.140 —
307 4.76 3 105 — — 0.022 0.131 —
310 8.48 3 105 — — 0.021 0.112 —
B*2705-m9-C8-LY 299 2.00 3 107 — — 0.026 0.152 —
303 1.25 3 107 — — 0.024 0.137 —
310 9.09 3 107 — — 0.021 0.108 —
323 3.23 3 106 — — 0.017 0.097 —
328 1.21 3 105 — — 0.015 0.093 2
334 2.38 3 104 — — 0.015 0.086 2
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were adapted to give the best fit of the data. The results of the
kinetic model fits are shown in Fig. 5, as colored lines (blue,
B*2705; red, B*2709). The agreement between data and model
is very good, especially in view of the errors in the kinetic
data points. At higher temperatures, however, a stretching
factor h had to be considered for the kinetics of B*2705-
m9-C8-LY to yield satisfactory fits. In Table 1, all model
parameters (fit results) are summarized.
Our simple model for the temperature dependence of the
peptide dissociation kinetics is successful for both subtypes
B*2705 and B*2709. The model describes correctly the slower
dissociation of the peptide from the subtype B*2705 as
compared to B*2709. For B*2709-m9-C6-LY, we observed
that the two time constants of the biexponential fit at a given
temperature do not differ by more than a factor of 5, whereas,
for B*2705-m9-C6-LY, the two time constants differ by more
than three orders of magnitude. This difference in peptide
dissociation kinetics between the two subtypes is also well
reproduced by the model (Table 1). In addition, the mono-
exponential kinetics for m9-C8-LY is satisfactorily described
by the modified model applying Eq. 17 (see Appendix).
The microscopic rate constants derived from our kinetic
model were used to obtain activation energies for the two
transitions in the peptide-dissociation process. The rate con-
stants listed in Table 1 were presented in Arrhenius plots (ln
k vs. 1/T), as shown in Fig. 6. Assuming a thermally acti-
vated peptide dissociation process, an activation energy was
determined for each rate constant k1, k1, and k2 from the
slope of a least-squares fit for each temperature-dependent
data set. The respective activation energies are summarized
in Table 2. The activation energies for full peptide release,
EA(krelease), are derived from k2 in the case of m9-C6-LY and
k1 in the case of m9-C8-LY.
By comparing EA(krelease), it can easily be seen that these
values are quite similar for both subtypes and both peptide
variants, since a value of ;150 kJ/mol was obtained in all
cases. This indicates that the underlying mechanism of full
peptide release described by the respective microscopic rate
constant (k2 in the case of m9-C6-LY and k1 in the case of
m9-C8-LY) is also similar in the two subtypes and inde-
pendent of the reporter group position. Based on x-ray struc-
ture analysis, arginine in position 2 of the peptide, close to
the N-terminus of the peptide, provides the primary anchor
of peptides bound to the B-pocket of the peptide binding
groove in HLA-B27 molecules (30), while the C-terminal
residue is regarded as a particularly important secondary anchor,
which binds within the F pocket. The peptide dissociation
process mainly reflects the unbinding of these anchors, al-
though every other amino acid may, in principle, contribute
to peptide binding stability and therefore to the peptide dis-
sociation process. As the difference between the two HLA-
B27 subtypes under investigation is a single amino-acid exchange
located in the F pocket, which does not effect stable ac-
commodation of the main anchor pArg2 of the peptide m9 in
the B pocket (12), we suggest that the similar activation
energies for full peptide release in both subtypes are asso-
ciated with the dissociation process of the main anchor pArg2
from the binding groove.
The activation energies for the first step in temperature-
induced m9-C6-LY dissociation, however, differ between the
two subtypes and point to distinct underlying mechanisms.
Surprisingly, EA(k1, k1) for the less thermally stable com-
plex B*2709-m9 is higher than for B*2705-m9. A compar-
ison of EA(krelease) with EA(k1, k1) for B*2709 shows that
similar activation energies of ;150 kJ/mol are found for the
first and the second transition in peptide dissociation from
FIGURE 6 Arrhenius plots of B*2705 and B*2709
complexed with m9-C6-LY and m9-C8-LY, respectively.
Rate constants result from the kinetic model described in
the text.
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the B*2709 complex. In addition, we also observed that the
values obtained for the rate constants k1, k1, and k2 are of
the same order of magnitude (Table 1, Appendix). For
B*2709, which lacks the C-terminal salt bridge between p9
and residue 116 in the F-pocket as compared to B*2705, we
consider an intermediate state in m9 dissociation (Pintermediate
in Eq. 7) that is characterized by a partially unbound peptide
as very likely, based on the idea that peptide dissociation
may start from the C-terminus (13,20). In contrast, the rate
constants obtained for the first and second steps in pep-
tide dissociation from the B*2705 complex differ by about
two to three orders of magnitude. Here, a scenario of a par-
tially unbound peptide seems very unlikely because of the
strong C-terminal anchor mediated by the pLys9-Asp116 salt
bridge. However, a conformational change of the peptide
binding pocket, leading to an intermediate state with a dif-
ferent peptide binding mode (Pintermediate in Eq. 7), may
account for the lower activation energy for the first step in
m9 dissociation from B*2705. The idea of a conformation-
ally altered peptide binding groove, leading to more confor-
mational freedom of the peptide but not to a partially unbound
peptide as suggested for B*2709-m9, is consistent with the
smaller amplitudes of the first kinetic component (Table S1)
observed for peptide release from B*2705-m9 (1.1–4% of
the total amplitude) compared to B*2709-m9 (9.5–76.1% of
the total amplitude). An altered peptide binding domain, prob-
ably connected to a b2m-induced conformational change (16),
was already reported for HLA-A2 molecules. In addition,
two different pathways for m9 dissociation from the two
HLA-B27 subtypes, including the involvement of b2m-
depleted HC/peptide heterodimers (15,16) cannot be ruled
out. Further experiments, dissecting the role of b2m on com-
plex stability and dynamics, were therefore performed.
Peptide dissociation kinetics in dependence of
b2m concentration reveal two different pathways
for B*2705 and B*2709
Since earlier studies in the field found evidence for an initial
b2m release in complex unfolding and suggested a role for
b2m in dampening conformational dynamics in the HLA-A2
heavy chain (15), we also monitored the kinetics of m9
dissociation in the presence of excess b2m. If there is fast
initial b2m release, we would expect the addition of excess
b2m to shift the b2m dissociation equilibrium toward the
fully assembled trimeric HLA-complex. While there was no
effect on our measured anisotropy decay curves in the case of
the subtype HLA-B*2709 at 30C (Fig. 7 B), the initial
anisotropy of subtype HLA-B*2705 at 60C as well as at
physiological temperature increased after addition of excess
of b2m as shown in Fig. 7 (A) (1000-fold excess) and Fig. 8
(2000-fold excess). Additionally, the mean decay constant of
the concentration of bound peptide is slower with an excess
of b2m. The time traces at 60C were fitted with stretched
exponentials and at 37C a biexponential decay law was ap-
plied; the results are summarized in Table 3. Note that the
value of the heterogeneity parameter h decreases with excess
of b2m, indicating a reduction in heterogeneity in the tri-
meric complex.
The data presented in Figs. 7 and 8 reveal that the effect of
b2m concentration on both the dissociation kinetics and the
steric restriction of the fluorophore LY bound to the peptide
m9 is exclusively observed for the B*2705 complexes.
Therefore, b2m seems to have a stabilizing effect on the
binding groove conformation of the B*2705 subtype and,
through long-range interactions, is indirectly involved in the
TABLE 2 Activation energies from the kinetic model
Subtype
EA(k1)
kJ mol1
EA(k1)
kJ mol1
EA(krelease)
kJ mol1
B*2709-m9-C6-LY 147.7 6 9.7 150.4 6 8.2 134.3 6 7.4
B*2709-m9-C8-LY — — 153.4 6 9.2
B*2705-m9-C6-LY 93.6 6 7.6 96.4 6 8.1 165.3 6 16.5
B*2705-m9-C8-LY — — 156.0 6 40.2
FIGURE 7 Kinetics of peptide dissociation measured via time-dependent
change in anisotropy of LY-labeled HLA-B*2705-m9-C6-LY with and
without b2m addition at 60C (A). Time-dependent change in anisotropy of
LY-labeled HLA-B*2709-m9-C6-LY with and without b2m addition at
30C (B). Conditions were chosen as in Fig. 2.
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dissociation of the peptide m9 from the B*2705 complex.
This result provides further implications for the nature of the
initial peptide dissociation step from B*2705, as will be
discussed below.
Current models of peptide release from MHC class I
molecules favor either parallel (16) or branched kinetics (15).
In both models, initial b2m dissociation from the hetero-
trimeric pMHC plays a role. Interestingly, for HLA-A2
complexes it was observed that an excess of b2m reduced the
amplitude of the first phase in the biphasic peptide dissoci-
ation time trace (15), leading the authors to assume that
the excess of b2m shifts the b2m dissociation equilibrium
toward the fully assembled heterotrimer. Accordingly, the
fast peptide dissociation phase results from initial dissoci-
ation of b2m, with subsequent rapid peptide release from the
HC/peptide dimer (15). In our study, however, addition of
b2m had no effect on the kinetics and the amplitudes of
B*2709-m9 complexes, while for B*2705 complexes excess
of b2m even slowed down peptide dissociation kinetics and
increased the amplitude of the first phase, thereby increasing
the steric restriction of peptide mobility by constituents of
the binding groove. Assuming initial b2m dissociation be-
fore peptide release, we would expect exactly the opposite
effect, i.e., a smaller amplitude for the first phase. We
therefore exclude fast initial b2m release as the origin of the
first peptide release component for B*2705-m9. Instead, we
suggest a b2m induced conformational change of the peptide
binding groove as the origin of the first phase before full
dissociation of m9 from B*2705. Comparable long-range
effects of b2m association with the heavy chain have been
reported to alter the peptide binding domain in HLA-A2
molecules, probably by a conformational change (16). In this
study, however, biphasic peptide dissociation kinetics was
interpreted as a result of the fully assembled trimeric complex
existing in two distinct conformations that exhibited differ-
ential stability. It was assumed that peptide dissociation from
the complex with the less stable conformation involved
initial b2m dissociation and subsequent fast peptide release,
while dissociation from the complex with the stable confor-
mation probably proceeded via at least one intermediate state
(16). These distinct dissociation mechanisms should result in
complex multiexponential kinetics, which, however, were not
observed in our experiments.
Based on these considerations, we favor a model for m9
dissociation from B*2705 being a two-step process, which
includes an intermediate state characterized by different in-
teractions of b2m with the heavy chain as compared to the
initial peptide bound state, leading to less restriction by the
peptide binding groove (Fig. 9 A) and therefore a decrease in
the anisotropy. About the nature of the different interaction
between b2m and complex and possible conformational changes
within b2m we can only speculate. However, our experi-
mental investigations and theoretical work show that the
peptide-binding groove is very sensitive to changes with regard
to b2m surrounding and degree of interaction to the protein
complex as well as b2m concentration. As, for B*2709-
m9, b2m excess had no significant effect on the peptide-
dissociation kinetics and the weak C-terminal interactions of
m9 within the F-pocket lead to an enhanced flexibility of the
peptide (13), we propose for B*2709 a two-step model with
the first step representing an equilibrium between the
peptide-bound state and a state with a partially unbound
peptide (Fig. 9 B).
SUMMARY
Aiming at a detailed dissection of antigen stability in two dif-
ferentially autoimmune-disease-associated HLA-B27 subtypes,
we have carried out various steady-state and time-resolved fluo-
rescence depolarization experiments to study thermodynamics
FIGURE 8 Time-dependent change in anisotropy of LY-labeled HLA-
B*2705-m9-C6-LY with and without addition of b2m at physiological
temperature. Conditions were chosen as in Fig. 2.
TABLE 3 Parameters of the exponential ﬁts of the kinetics of peptide dissociation from HLA-B*2705-m9-C6 with and without addition
of b2m observed by time-dependent detection of the stationary anisotropy
60C 37C
A t/s h A1/% t1/s A2/% t2/s
W/o excess b2m 0.0875 4.14 3 10
3 1.50 2.9 3.60 3 102 97.1 8.32 3 105
With excess b2m 0.0881 7.69 3 10
3 1.21 4.6 1.39 3 104 95.4 2.30 3 106
For the kinetics at 60C, stretched exponential decay and for those at 37C, biexponential decay laws were applied.
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and kinetics of peptide dissociation using fluorescently-
labeled peptides. In this report, we have focused on the
peptide m9 (GRFAAAIAK). C-terminal lysine or arginine, as
found in the sequence of the m9 peptide, account for ;27%
of the natural B*2705 ligands (11). Analysis of peptide-
dissociation kinetics is important, as differences in peptide
affinity are mainly due to differences in peptide-dissociation
constants (16).
Our data reveal two different pathways for m9 dissociation
from B*2705 and B*2709, underscoring the quantitative
differences in the binding properties of peptides bearing a
C-terminal Lys with the two differentially AS-associated sub-
types. Fast peptide-release kinetics, with time constants of
;1 h at physiological temperature as observed for B*2709,
explain the low probability of native peptides with basic
C-terminal anchor residues to be eluted from that B27 sub-
type (11,29). Simulation of the dissociation kinetics with a
two-step kinetic model revealed similar activation energies
of ;130–150 kJ/mol for the two transitions observed for
peptide dissociation from B*2709, dominated by the disso-
ciation of the C-terminal and the primary R2 anchor, re-
spectively. For the disease-associated subtype B*2705, an
intermediate state in the peptide-dissociation pathway was
observed, which is characterized by a b2m-coupled confor-
mational change of the peptide binding pocket. Such allosteric
mechanisms, controlling the interactions between the com-
ponents of the trimeric HLA complex, not only govern its
assembly and dissociation (16) but might also influence
recognition by T-cell receptors. At physiological tempera-
ture, the transition to the intermediate state with altered b2m/
HC interaction occurs within minutes, while final peptide
release lasts for ;10 days and thus determines the peptide-
HLA-B*2705 conformation, which will be recognized by
cellular ligands of the immune system, such as T-cell receptors.
The finding that b2m contributes, in a subtype-dependent
fashion, to the stability of pMHC, adds not only to an under-
standing of the mechanism of pMHC dissociation, but may
be relevant for the pathogenesis of AS as well (31). A recent
study employing rats transgenic for B*2705 and human b2m
(to different levels of expression) showed that b2m is inti-
mately connected with the occurrence of a variety of dis-
eases. Only rats with very high levels of human b2m suffered
from AS-related symptoms, indicating the importance of
human b2m (and B*2705 complexes with human b2m) for
disease development. However, as pointed out previously
(31), there are important differences between the develop-
ment of AS in humans and transgenic animals, in particular
with regard to the number of HLA-B27 and b2m gene copies
present (each maximally two in humans, each .20 in
diseased rats homozygous for the respective locus) and the
time course of disease progression (decades in humans,
,1 year in rats with high HLA-B27 and b2m copy numbers).
Nevertheless, the successful reconstitution of the B*2705-
m9 complex with covalent b2m-dimers described in our study
provides, in this context, additional insight into the variety of
interactions that may occur within HLA-complexes.
In summary, evidence has been presented in this study that
an allosteric mechanism, intimately connected with b2m,
controls m9 peptide presentation and dissociation from
B*2705. The described differences in complex stability and
peptide presentation modes between the differentially AS-
associated B*2705 and B*2709, as well as the appearance of
long-range interactions between b2m and the peptide-binding
groove in the strong AS-associated subtype B*2705, are
solely due to the natural polymorphism in the single amino-
acid position 116 at the floor of the peptide-binding groove.
APPENDIX
The kinetic model (Eq. 7) can be described with a set of differential
equations for the change in concentrations of 1), peptides bound to the
complex [Pbound]; 2), intermediately bound peptides [Pint]; and 3), peptides
completely dissociated from the complex [Punbound]. In the case of m9-C6-
LY, the following equations apply:
d½Pbound
dt
¼ k1½Pbound1 k1½Pint; (8)
d½Pint
dt
¼ k1½Pbound  k1½Pint  k2½Pint; (9)
d½Punbound
dt
¼ k2½Pint: (10)
Since we assume an equilibrium process of the first dissociation process
(Eq. 7), i.e., [Pbound] 1 [Punbound] ¼ const., the change in concentration of
the intermediately bound peptide becomes zero, d[Pint]/dt ¼ 0. An
expression for the change in concentration of the bound peptide [Pbound]
can then be obtained:
d½Pbound
dt
¼ k11 k1 k1
k11 k2
 
½Pbound: (11)
Separation of variables and integration of Eq. 11 gives
FIGURE 9 Model for m9 peptide dissociation from HLA-B*2705 (A) and
HLA-B*2709 (B).
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½PboundðtÞ ¼ ½Pbound0 exp

k11 k1 k1
k11 k2
 
t

; (12)
with [Pbound]0 as the initial concentration within the heterotrimeric complex.
As the fluorescence anisotropy directly reflects the mole fraction of peptide
molecules bound to the pMHC and the fraction of peptide free in solution,
the change in concentration of the bound peptide [Pbound] is monitored by
the decrease in anisotropy r(t):
rðtÞ  rN[ ½PboundðtÞ; (13)
rðt ¼ 0Þ  rN[ ½Pbound0: (14)
Since the anisotropy of the free peptide is not zero, a corresponding
temperature-dependent offset, rN, has to be added to Eq. 12, yielding the
correct concentration-time profile:
½PboundðtÞ ¼ ½Pbound0 exp

k11 k1 k1
k11 k2
 
t

1 rN: (15)
For the dissociation of the peptide m9-C8-LY from B*2705 and B*2709, we
observed monoexponential kinetics at moderate temperatures and biexpo-
nential kinetics at higher temperatures as well as slightly slower kinetics
compared to the corresponding values observed with the peptide m9-C6-LY
(Fig. 5, B and D). Under the assumption that an interaction between C-LY in
position 8 of the peptide and residues of the binding groove results in a
shifted equilibrium toward the bound peptide, the kinetic model described
above is modified in the following way. The rate constants for the first
reaction step and for the back reaction become much smaller than the rate
constant for the full release of the peptide
k1; k1  k2; (16)
so that the quotient in Eq. 14 approaches zero. Thus, only the slowest rate
constant determines the speed of the reaction as described by Eq. 17:
½PboundðtÞ ¼ ½Pbound0 expðk1 tÞ1 rN: (17)
Note added in proof: Under the assumption that the rates in our kinetic
model follow a simple Arrhenius law and the anisotropy values of the three
different states have linear temperature dependence, the system of coupled
differential equations describing our kinetic model can be solved in the
form of a sum of two exponential functions and the respective activation
energies can be determined using a global fit to data sets at five different
temperatures. The activation energies from this fit (B*2705-m9-C6-LY:
EA(k1)¼ 118 kJ/mol, EA(k1)¼ 100 kJ/mol, EA(k2)¼ 155 kJ/mol; B*2709-
m9-C6-LY:EA(k1)¼ 130 kJ/mol, EA(k1)¼ 145 kJ/mol,EA(k2)¼ 131 kJ/mol)
agree with the values obtained from the simplified approach described
above. The anisotropy in the intermediate state (Pmt) amounts to 93%
(B*2705-m9-C6-LY) and 36% (B*2709-m9-C6-LY) of the anisotropy
value obtained for the respective peptide-bound state.
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